These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 6595483

  • 21. Quantitation of chemosensitivity in acute myelocytic leukaemia.
    Lihou MG, Smith PJ.
    Br J Cancer; 1983 Oct; 48(4):559-67. PubMed ID: 6578837
    [Abstract] [Full Text] [Related]

  • 22. Different sensitivity of normal and leukaemic progenitor cells to Ara-C and IL-3 combined treatment.
    Lista P, Brizzi MF, Rossi M, Resegotti L, Clark SC, Pegoraro L.
    Br J Haematol; 1990 Sep; 76(1):21-6. PubMed ID: 2223644
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Effect of the interval between exposures to cytarabine on its cytotoxic action on HL-60 myeloid leukemic cells.
    Leclerc JM, Momparler RL.
    Cancer Treat Rep; 1984 Sep; 68(9):1143-8. PubMed ID: 6592037
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The BN acute myelocytic leukemia (BNML) (a rat model for studying human acute myelocytic leukemia (AML)).
    Martens AC, Van Bekkum DW, Hagenbeek A.
    Leukemia; 1990 Apr; 4(4):241-57. PubMed ID: 2195239
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The use of haemoregulatory peptides (pEEDCK monomer and dimer) for reduction of cytostatic drug induced haemopoietic damage.
    Paukovits WR, Moser MH, Binder KA, Paukovits JB.
    Cancer Treat Rev; 1990 Sep; 17(2-3):347-54. PubMed ID: 2272050
    [Abstract] [Full Text] [Related]

  • 36. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 37. Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow.
    Tanaka M.
    Leuk Res; 1993 Jul; 17(7):585-92. PubMed ID: 8326741
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo.
    Hubeek I, Comijn EM, Van der Wilt CL, Merriman RL, Padron JM, Kaspers GJ, Peters GJ.
    Oncol Rep; 2008 Jun; 19(6):1517-23. PubMed ID: 18497959
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.